Comparison of two palliative radiotherapy schedules of radiotherapy in locally advanced head and neck cancer

Abstract

Background and Aims: Head and neck cancer accounts for 4.8% of all cancers globally and 13.9% of all cancers in India.1 In Indian setting, more than 70% patients present in locally advanced stage and with poor general condition and are suitable candidates for palliative radiotherapy. The present prospective, randomized study was planned to comparatively evaluate the efficacy, tolerability and toxicity of two schedules of palliative radiotherapy in patients of locally advanced head & neck cancer (LAHNC).

Methods: The present study was carried out on histopathologically proven and inoperable 60-patients of LAHNC. Patients in group I received total external radiation dose of 40Gy, 4Gy/fraction, and 2fractions a week for 5weeks. Group II patients received 20Gy in 5fractions in 5days followed by 3week gap followed by 20Gy in 5fractions in 5days. The groups were compared in terms of local tumor control and adverse effects of radiation.

Results: All patients were of stage IV and 83% had nodal involvement. At the end of treatment for local disease, complete response (CR) in group I was better than group II (13.2% vs 3.3%) and complete nodal response was seen in 17% patients in each group. Disease status at 6months of follow up was 27% vs 23% complete tumor response and 30% vs 24% complete nodal response in group I and II respectively. Overall no evidence of disease (NED) was seen in 13% in group I and 17% in group II. Grade 3 skin radiation reactions were only seen in 1-patient of group II, however, grade 3 mucosal radiation reactions were seen in 20% patients in group I and 7% in group II. Seven patients in group I required nasogastric feeding tube as compared to 3-patients in group II. Grade 3 subcutaneous toxicity was equally present in 3% in each group.

Conclusions: In this study we observed that both the schedules of radiotherapy are equally effective in tumor control and have comparable toxicity profile. Hence, to decrease the patient load in tertiary care institutes, it is recommended to use fractionation schedule with two radiotherapy fractions per week.

Keywords: head and neck cancer, palliative radiotherapy, early radiation reaction, late radiation toxicity, tumor control, LAHNC

Abbreviations: EBRT, external beam radiation therapy; LAHNC, locally advanced head and neck cancer; HNC, head & neck cancer; ICD, international classification of diseases; SGOT, serum glutamic-oxaloacetic transaminase; SGPT, serum glutamic-pyruvic transaminase; NED, no evidence of disease; CR, complete response; PR, partial response; AJCC, american joint committee on cancer; RTOG, radiation therapy oncology group; SWOG, south west oncology group; QOL, quality of life

Introduction

Majority of patients of head and neck cancer present in locally advanced stage, and thus, local failure rates are as high as 50-70%.1-3 Radiotherapy alone or in combination with chemotherapy is the standard non-surgical therapy for LAHNC. The goal of treatment in these patients is to achieve prompt relief of distressing symptoms. There have been some reports on the use of hypofractionated radiotherapy for palliation in LAHNC but many are methodologically flawed, with limited or no toxicity data and no assessment of response of tumor to palliative radiotherapy.4 The present prospective, randomized study was planned to comparatively evaluate the efficacy, tolerability and toxicity of two schedules of palliative radiotherapy in LAHNC.

Material and methods

The present study was carried out on histopathologically proven and inoperable 60 patients of LAHNC. These patients were randomly divided in two groups of 30 patients each by draw of lots. The patients were staged according to AJCC 2010 TNM staging system. All patients in group I (study group) received total radiation dose of 40Gy, 4Gy/fraction, 2fractions a week for 5weeks. Group II patients (control group) received 20Gy in 5fractions in 5days followed by 3week gap followed by 20Gy in 5fractions in 5days. Tumor response (both primary and nodal response) was assessed by WHO response criteria either clinically or if needed, radiologically.3 Radiation reactions were assessed by Radiation Therapy Oncology Group (RTOG) criteria.6 Both tumor response and radiation reactions were compared at the end of treatment and 6month follow-up.
Results and discussion

The male to female ratio was 11:1 in both the groups. Most of the patients were of rural background (76%) and chronic smokers (88%). Fifty two percent patients were both chronic smokers as well as alcoholics. Most of the primary lesions were ulcer proliferative (53%) and most common histopathology was moderately differentiated squamous cell carcinoma (80%). Throat pain was most common chief complaint presenting in 37% patients. Most common primary site involved was base of tongue in 40% of patients. All patients were of stage IV and 83% had nodal involvement. At the end of treatment for local disease, complete response (CR) in group I was better than group II (13% vs 3%). Partial response (PR) at the end of treatment was more in group II (84%) compared to 74% in group I. Each group had equal patients (13%) with no response in local disease at the end of treatment. At the end of treatment complete nodal response was seen in 17% patients in each group and partial nodal response was slightly better in group II (67%) as compared to 60% in group I.

At the end of treatment, grade 2 skin reactions were 20% and 24% in group I and II respectively while grade 3 skin reactions was only seen in 1 patient of group II. Grade 2 mucosal reactions were 37% and 23% in group I and II respectively while grade 3 mucosal reactions was seen in 20% patients in group I and 7% in group II.

Grade 2 pharyngeal complications were 53% vs 57% and esophageal complications were 23% vs 10% in group I and II respectively. Seven patients in group I required nasogastric feeding tube as compared to three patients in group II. According to South West Oncology Group (SWOG) criteria, 7 patients (23%) in group I experienced grade 2 weight loss over the course of treatment compared to 6 patients (20%) in group II.

Disease status at 6 months of follow up was noted as 26% vs 23% complete tumor response and 30% vs 23% complete nodal response in group I and II respectively. Overall no evidence of disease (NED) was seen in 13% in group I and 17% in group II (Table 1). Grade I late radiation skin toxicity was higher in group II (53% vs 67%), however, grade 2 late radiation skin toxicity was higher in group I than group II (33% vs 13%). Grade I late radiation subcutaneous toxicity was higher in group I (30% vs 17%) but grade 2 was higher in group II (57% vs 63%). Grade 3 subcutaneous toxicity was equally present in 3% in each group. Grade 1 late radiation mucosal toxicity was higher in group II (33% vs 43%) whereas grade 2 was higher in group I (57%) as compared to 47% in group II (Table 2).

In third world countries as is India, incidence of LAHNC is quite high. According to hospital-based retrospective study of all patients in 12 years study in Regional Cancer Centre, PGIMS Rohtak from the year 2001 to 2012, Head and neck cancer comprises around 37.8% of all malignancies. Most of the cases are in advanced stage with poor general condition and the distressing symptoms warrants palliation of the symptoms with radiotherapy. Improvement in symptoms along with QOL is an important aspect of palliation. As there is no standard schedule for palliative radiotherapy in LAHNC various palliative schedules have been tried ranging from 20 Gy in 5 fractions to 40-50 Gy in 10 to 15 fractions which had variable tumor response and radiation reactions.16

Similar studies had shown that in LAHNC, palliative radiotherapy can achieve 70-80% local tumor control at the end of treatment and 20-30% patients with no clinical disease with less than 10% severe late radiation reactions at the end of 6 months follow up.4,5,8

Table 1 Disease status at the end of six month follow up

| Tumor             | Group I | Group II | P value |
|-------------------|---------|----------|---------|
| Complete response(CR) | 08(26.4%) | 07(23.4%) | 0.766   |
| Partial response(PR)  | 11(36.3%) | 12(40%)  | 0.592   |
| Recurrence          | 08(26.4%) | 09(30%)  | 0.744   |
| Death              | 03(10.0%) | 02(6.6%) | 0.389   |
| Nodal              |         |          |         |
| Complete response(CR) | 09(30%)  | 07(23.3%) | 0.559   |
| Partial response(PR)  | 05(16.6%) | 08(26.7%) | 0.347   |
| Recurrence          | 08(26.7%) | 08(26.7%) | 1.00    |
| Death              | 03(10.0%) | 02(6.6%) | 0.389   |
| No lymph node(N0) palpable at time of presentation | 05(16.6%) | 05(16.6%) | 1.00 |
| Overall             |         |          |         |
| No evidence of disease(NED) | 04(13.3%) | 05(16.6%) | 0.718   |
| Partial response(PR)  | 14(46.7%) | 14(46.7%) | 0.347   |
| Recurrence          | 09(30.0%) | 09(30.0%) | 1.00    |
| Death              | 03(10.0%) | 02(6.7%) | 0.64    |

Table 2 Late radiation reactions at end of six month follow up

| Cutaneous          | Group I | Group II | P value |
|--------------------|---------|----------|---------|
| Grade 0            | 03(10%) | 06(20%)  | 0.278   |
| Grade 1            | 16(53.4%) | 20(66.7%) | 0.292   |
| Grade 2            | 10(33.3%) | 04(13.3%) | 0.067   |
| Grade 3            | 01(3.3%)  | 00(0%)   | None    |

Subcutaneous

| Grade 0            | 03(10%) | 05(17%)  | 0.448   |
| Grade 1            | 09(30%) | 05(17%)  | 0.222   |
| Grade 2            | 17(56.7%) | 19(62.7%) | 0.598   |
| Grade 3            | 01(3.3%)  | 01(3.3%) | 1.00    |

Mucosal

| Grade 0            | 02(6.7%) | 03(10%)  | 0.64    |
| Grade 1            | 11(33%)  | 13(41.3%) | 0.598   |
| Grade 2            | 17(57%)  | 14(46.7%) | 0.438   |
| Grade 3            | 01(3.3%)  | 00(0%)   | None    |
In this present study complete local response at the end of treatment was better in group I than group II (13.2% vs 3.3%). Partial response at the end of treatment was more in group II (84%) compared to 74% in group I. Acute grade 3 skin reactions was only seen in 1-patient of group II whereas grade 3 mucosal reactions was seen in 20% patients in group I and 7% in group II. Seven patients in group I required nasogastric feeding tube as compared to three patients in group II.

No evidence of disease (NED) was seen in 13% in group I and 17% in group II at 6-month of follow up. Grade 3 late radiation skin and mucosal toxicity was higher in group I (3.3% each) as compared to group II (0% each). Grade 3 subcutaneous toxicity was equally present in 3% in each group. These results were similar and in accordance to the similar studies done by various authors. A few of those studies and their results are described in Table 3.

Table 3 Comparison of different studies with disease response, acute and late skin and mucosal reactions

| S.No | Reference       | Dose and fractionation                  | Disease response | Acute grade 3 skin reactions | Acute grade 3 mucosal reactions | NED status at the end of 6months | Late grade 3 skin radiation toxicity- skin | Late grade 3 mucosal radiation toxicity- skin |
|------|----------------|----------------------------------------|------------------|-------------------------------|---------------------------------|-----------------------------------|------------------------------------------|------------------------------------------|
| 1    | Agarwal et al.  | 40Gy in 16 fractions in 3.1 weeks      | CR-10%           | 14%                           | 63%                             | _                                 | 9%                                      | _                                        |
|      |                 |                                        | PR-63%           |                               |                                 | _                                 | _                                        | _                                        |
| 2    | Das et al.      | 40Gy in 10 fractions in 5 weeks with 2 fractions/week | 3%               | 18%                           | _                               | _                                 | _                                        | _                                        |
|      |                 |                                        | 14.8Gy in 4 fractions thrice, three weekly(quad shot) | Local control-84%         | 28%                             | 36%                               | 20%                                     | 3.30%                                   | 3.30%                                   |
| 3    | Soni et al.     | 50Gy in 16 fractions in 3.1 weeks      | Local control-76%| 44%                           | 56%                             | 28%                               | 6.70%                                   | 10%                                     |
|      |                 |                                        | 20Gy in 5 fractions in 5 days twice, three weeks apart(total 40Gy/10 fractions/5weeks) | Local control-76% | 16%                             | 24%                               | 16%                                     | _                                        |
| 4    | Kancherla et al.| 20Gy in 5 fractions in 5 days twice, two weeks apart(total 40Gy/10 fractions/4weeks) | CR-39%           | _                             | _                               | _                                 | _                                        | _                                        |
|      |                 |                                        | PR-33%           | 3%                            | 6%                              | _                                 | _                                        | _                                        |
| 5    | Present study   | 40Gy in 10 fractions in 5 weeks with 2 fractions per week(group I) | Local tumor CR-13.2%| 0%                            | 20%                             | 13%                               | 3.30%                                   | 3.30%                                   |
|      |                 |                                        | PR-74            |                               |                                 | _                                 | _                                        | _                                        |

Citation: Kumar T, Dhull AK, Atri R, et al. Comparison of two palliative radiotherapy schedules of radiotherapy in locally advanced head and neck cancer. J Cancer Prev Curr Res. 2018;9(4):164–167. DOI: 10.15406/jcpcr.2018.09.00342
Conclusion

In this study, we observed that both the schedules of radiotherapy are equally effective in tumor control and have comparable toxicity profile. Thus, we conclude that 40Gy in 10fractions in 5weeks either by 2fractions per week for 5weeks or by 5fractions in 5days followed by gap of 3weeks followed by 5fractions in 5days are equally effective in LAHNC for palliative radiotherapy. Hence, to decrease the patient load in tertiary care institutes, it is recommended to use fractionation schedule with two radiotherapy fractions per week.\textsuperscript{11,12}

Acknowledgements

None.

Conflict of interest

Author declares that there is no conflict of interest

References

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. \textit{Int J Cancer}. 2015;136(5):E359–86.
2. Lamont EB, Vokes EE. Chemotherapy in the management of squamous-cell carcinoma of the head and neck. \textit{Lancet Oncol}. 2001;2:261–269.
3. Stupp R, Weichselbaum RR, Vokes EE. Combined modality therapy of head and neck cancer. \textit{Semin Oncol}. 1994;21(3):349–58.
4. Soni A, Kaushal V, Verma M, et al. Comparative Evaluation of Three Palliative Radiotherapy Schedules in Locally Advanced Head and Neck Cancer. \textit{World Journal of Oncology}. 2017;8(1):7–14.
5. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. \textit{Ann Surg Oncol}. 2010;17(6):1471–4.
6. De Jager R, Longeval E, Klustersky J. High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party (Belgium). \textit{Cancer Treat Rep}. 1980;64(12):1341–6.
7. Mohanti BK, Unnapathy H, Bahadur S, et al. Short course palliative radiotherapy of 20Gy in 5 fractions for advanced and incurable head and neck cancer: AIIMS study. \textit{Radiother Oncol}. 2004;71(3):275–80.
8. Agarwal JP, Nemeth B, Murthy V, et al. Hypofractionated palliative radiotherapy for advanced head and neck cancer. \textit{Radiother Oncol}. 2008;89(1):51–6.
9. Das S, Vithayathil A, Pal SK, et al. Hypofractionated Palliative Radiotherapy in Locally Advanced Inoperable Head and Neck Cancer: CMC Vellore Experience. \textit{Indian J Palliat Care}. 2013;19(2):93–8.
10. Kancherla KN, Oksuz DC, Prestwich RJ, et al. The role of split-course hypofractionated palliative radiotherapy in head and neck cancer. \textit{Clin Oncol (R Coll Radiol)}. 2011;23(2):141–8.
11. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). \textit{Int J Radiat Oncol Biol Phys}. 1995;31(5):1341–6.
12. Dhull AK, Atri R, Kaushal V. Alcohol as a risk factor in HNC, an enormous toll on the lines and communities. \textit{J Evid Based Med Health}. 2016;3:354–60.

\textbf{Citation}: Kumar T, Dhull AK, Atri R, et al. Comparison of two palliative radiotherapy schedules of radiotherapy in locally advanced head and neck cancer. \textit{J Cancer Prev Curr Res}. 2018;9(4):164–167. DOI: 10.15406/jcpcr.2018.09.00342